Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2003

View Archived Issues

Evidence of antiinflammatory effects for efalizumab in atopic asthma

Potential cognitive benefits suggested for donepezil and vitamin E in AD

Early response to antivirals predicts sustained response in chronic hepatitis C

Phase II laquinimod study for MS meets primary endpoint according to first analysis

Clofarabine enters pivotal European trial for ALL

Cerezyme approved for type 3 Gaucher's disease in E.U.

Genzyme completes acquisition of SangStat

Phase II program of ISIS-113715 follows encouraging phase I data

FDA approves expanded Synagis labeling for children with congenital heart disease

Medtronic acquires remaining rights to rhBMP-2

Roche and ParAllele form type 2 diabetes genetic collaboration

SBIR grant supports development of melanoma peptide vaccine

Genmab delivers antibody targeting IL-15 receptor to Amgen

Thymitaq studied in new phase I/II trial in combination with Taxotere

Lilly licenses Antares drug delivery technology

First dose level completed in phase Ib DVT trial of ThromboView

Acceptable safety profile described for NBI-3001 in recurrent malignant glioma

AstraZeneca claims novel KDR inhibitors for cancer and other disorders

Two series of piperidine-based antibacterial agents prepared and tested at GSK

New tripeptides with HCV NS3-inhibitory activity covered by Boehringer Ingelheim patent

Novo Nordisk and Boehringer Ingelheim present new histamine H3 modulators

Novel antitumor protein kinase inhibitors in early development at Vertex

Canadian scientists design new photosensitizers for cancer, ocular disorders, etc.

HARP antibiotics: a novel class for resistant Gram-positive infections

Potent and selective CCR5 antagonist for HIV highlighted by Pfizer at ICAAC

Orally bioavailable meropenem prodrugs designed by Japanese group

Aminomethylcycline antibiotic profiled at ICAAC meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.